Revance Releases Fourth Quarter and Full Year 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Revance Theraputics (RVNC) Pipeline is Underappreciated - Guggenheim
March 3, 2016 9:05 AM ESTGuggenheim analyst, Louise Chen, believes Revance Therapeutics' (NASDAQ: RVNC) pipeline prospects are underappreciated. She expects five launches over five years beginning in '19 that should drive upward earnings revisions and multiple expansion to levels not reflected in consensus expectations. No change to Buy rating or $55 PT.
The launches include:
1) RT001, topical for Crows Feet Lines in '19
2) RT002, injectable for glabellar... More
Revance Therapeutics (RVNC) Tops Q4 EPS by 3c
March 2, 2016 4:29 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($0.83), $0.03 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $60 thousand.
For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.
... More